Arbutus Biopharma Corp (ABUS) stock
ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 12/3082% below fair value
$3.88+0.06 (+1.57%)
Close on Nov 11, 2026Market cap $767.65MP/E 3.5Yield –
Arbutus Biopharma operating margin
Operating margin is operating income as a percentage of revenue.
Arbutus Biopharma's operating margin for the twelve months ending Sep 30, 2026 was 81.1%. For fiscal 2025 it was -271.0%, against -1236.7% the year before. The highest annual figure on record is -63.6% in fiscal 2011.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -271.0% | +965.8 |
| FY2024 | Dec 31, 2024 | -1236.7% | −806.2 |
| FY2023 | Dec 31, 2023 | -430.5% | −262.8 |
| FY2022 | Dec 31, 2022 | -167.8% | +501.4 |
| FY2021 | Dec 31, 2021 | -669.1% | +167.0 |
| FY2020 | Dec 31, 2020 | -836.1% | +1557.9 |
| FY2019 | Dec 31, 2019 | -2394.0% | −883.8 |
| FY2018 | Dec 31, 2018 | -1510.2% | −473.4 |
| FY2017 | Dec 31, 2017 | -1036.7% | +31937.0 |
| FY2016 | Dec 31, 2016 | -32973.8% | −32527.3 |
| FY2015 | Dec 31, 2015 | -446.5% | −222.9 |
| FY2014 | Dec 31, 2014 | -223.6% | −145.0 |
| FY2013 | Dec 31, 2013 | -78.6% | +13.2 |
| FY2012 | Dec 31, 2012 | -91.8% | −28.2 |
| FY2011 | Dec 31, 2011 | -63.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -3509.7% | −1872.8 |
| Q2 FY2026 | Jun 30, 2026 | -588.2% | −602.0 |
| Q1 FY2026 | Mar 31, 2026 | 94.3% | +1551.2 |
| Q4 FY2025 | Dec 31, 2025 | -503.3% | +381.9 |
| Q3 FY2025 | Sep 30, 2025 | -1636.9% | −35.7 |
| Q2 FY2025 | Jun 30, 2025 | 13.9% | +1264.3 |
| Q1 FY2025 | Mar 31, 2025 | -1456.9% | −193.0 |
| Q4 FY2024 | Dec 31, 2024 | -885.2% | +82.0 |
| Q3 FY2024 | Sep 30, 2024 | -1601.2% | −1138.4 |
| Q2 FY2024 | Jun 30, 2024 | -1250.5% | −855.2 |
| Q1 FY2024 | Mar 31, 2024 | -1263.9% | −1003.5 |
| Q4 FY2023 | Dec 31, 2023 | -967.2% | −605.9 |
| Q3 FY2023 | Sep 30, 2023 | -462.8% | −163.6 |
| Q2 FY2023 | Jun 30, 2023 | -395.3% | −296.2 |
| Q1 FY2023 | Mar 31, 2023 | -260.4% | −173.2 |
| Q4 FY2022 | Dec 31, 2022 | -361.3% | +287.4 |
| Q3 FY2022 | Sep 30, 2022 | -299.2% | +251.9 |
| Q2 FY2022 | Jun 30, 2022 | -99.1% | +701.4 |
| Q1 FY2022 | Mar 31, 2022 | -87.2% | +654.7 |
| Q4 FY2021 | Dec 31, 2021 | -648.7% | +34.5 |
| Q3 FY2021 | Sep 30, 2021 | -551.1% | +448.0 |
| Q2 FY2021 | Jun 30, 2021 | -800.4% | +67.5 |
| Q1 FY2021 | Mar 31, 2021 | -741.9% | +139.9 |
| Q4 FY2020 | Dec 31, 2020 | -683.2% | +125.6 |
| Q3 FY2020 | Sep 30, 2020 | -999.1% | +1974.6 |
| Q2 FY2020 | Jun 30, 2020 | -868.0% | +2293.6 |
| Q1 FY2020 | Mar 31, 2020 | -881.8% | +1945.3 |
| Q4 FY2019 | Dec 31, 2019 | -808.8% | +198.5 |
| Q3 FY2019 | Sep 30, 2019 | -2973.7% | −930.5 |
| Q2 FY2019 | Jun 30, 2019 | -3161.6% | −1389.4 |
| Q1 FY2019 | Mar 31, 2019 | -2827.1% | −1545.4 |
| Q4 FY2018 | Dec 31, 2018 | -1007.3% | +1370.3 |
| Q3 FY2018 | Sep 30, 2018 | -2043.2% | −1856.1 |
| Q2 FY2018 | Jun 30, 2018 | -1772.2% | +103.2 |
| Q1 FY2018 | Mar 31, 2018 | -1281.7% | +6505.1 |
| Q4 FY2017 | Dec 31, 2017 | -2377.6% | – |
| Q3 FY2017 | Sep 30, 2017 | -187.1% | – |
| Q2 FY2017 | Jun 30, 2017 | -1875.4% | – |
| Q1 FY2017 | Mar 31, 2017 | -7786.8% | – |
See a number that looks wrong?